Dr Hui-Ming Lin

Back to

Book Chapters | 2016

, 2016, '- Metabolomics: An Important Tool for Assessing State of Health and Risk of Disease in Nutrigenomics Research', in Nutrigenomics and Nutrigenetics in Functional Foods and Personalized Nutrition, CRC Press, pp. 248 - 261, http://dx.doi.org/10.1201/b15369-15

Book Chapters | 2016

Lin HM; Rowan D, 2016, 'Metabolomics: An important tool for assessing state of health and risk of disease in nutrigenomics research', in Nutrigenomics and Nutrigenetics in Functional Foods and Personalized Nutrition, pp. 229 - 242
Journal articles | 2026

Cilento MA; Lin HM; Yeung N; Kim RMN; Portman N; Stockler MR; Martin AJ; Subhash V; Yip S; Butler LM; Marschner IC; Meikle PJ; Azad AA; Davis ID; Horvath LG; Sweeney CJ, 2026, 'Insulin-Like Growth Factor Axis and Survival in Metastatic Hormone-Sensitive Prostate Cancer: Post-Hoc Analysis From the ENZAMET Phase 3 Trial', Prostate, http://dx.doi.org/10.1002/pros.70245

Journal articles | 2026

Ciliberti E; Nerone M; Ricco V; Lin H-M; Marmé F; Sessa C; Coquard IR; Moore KN; Colombo I, 2026, 'Antibody drug conjugates in gynaecological cancers: navigating between opportunities and challenges', EClinicalMedicine, 97, pp. 103895, http://dx.doi.org/10.1016/j.eclinm.2026.103895

Journal articles | 2026

Fanti S; Turco F; Tombal B; Walz J; Hofman MS; Hadaschik B; Emmett L; Tilki D; Pecoraro G; Salfi G; Attard G; Beltran H; Bjartell A; Briganti A; Burger IA; Castro E; Cerci JJ; Chiti A; Cooperberg M; Fizazi K; Fossati N; Gafita A; Gallina A; Goffin K; Horvath LG; Hugosson J; Iagaru A; James ND; Kasivisvanathan V; Koh DM; Kristiansen G; Kumar R; Lecouvet F; Loeb S; McKay RR; Morris MJ; Murphy DG; Murthy V; Naoun N; Oprea-Lager DE; Ost P; O’Sullivan J; Padhani AR; Palapattu G; Paone G; Petralia G; Roobol MJ; Sartor OA; Sathekge M; Schuster DM; Seibert TM; Spratt DE; Tempany C; Tunariu N; Vargas HA; Vogl UM; Wyatt AW; Zilli T; Lin HM; Omlin A; Gillessen S; Herrmann K, 2026, 'Diagnosis and Staging of Patients with Prostate Cancer: Report from the 2025 Advanced Prostate Cancer Consensus Conference (APCCC) Diagnostics', European Urology, 90, pp. 347 - 376, http://dx.doi.org/10.1016/j.eururo.2026.06.009

Journal articles | 2026

Gillessen S; Gobat K; Cathomas R; Fischer N; Pereira Mestre R; Hermanns T; Rothschild SI; Mach N; Mingrone W; Ciriolo M; Müller B; Erdmann A; Schär C; Mamot C; Bohanes P; Omlin A; Bastian S; Ribi K; Mazzucchelli L; Barizzi J; Horvath LG; Scheinberg T; Mellor R; Schär S; Lin HM; Lim R; Pollak M; Turco F; Rothermundt C, 2026, 'Enzalutamide Plus Metformin Versus Enzalutamide Alone in Metastatic Castration-resistant Prostate Cancer: A Randomized Phase 2 Trial (SAKK 08/14)', European Urology Oncology, 9, pp. 822 - 832, http://dx.doi.org/10.1016/j.euo.2026.03.001

Journal articles | 2026

Medina S; Tokuyama N; Putcha V; Pathak T; Fu P; Thomas H; Subhash VV; Yip S; Lin HM; Horvath LG; Kench JG; Zhang A; Stockler MR; Joshua AM; Azad A; Oakes SR; Davis ID; Sweeney CJ; Madabhushi A, 2026, 'AI-Based Pathology Classifier Predicts Sensitivity to Enzalutamide in Metastatic Hormone-Sensitive Prostate Cancer: A Biomarker Analysis of the ENZAMET Trial', Clinical Cancer Research, 32, pp. 4742 - 4753, http://dx.doi.org/10.1158/1078-0432.CCR-26-0871

Journal articles | 2026

Pecoraro G; Cuzzocrea M; Iacovitti CM; Puglisi M; Martinello C; De Giorgi A; Merler S; Tortola L; Lin H-M; Leone G; Turco F; Mestre RP; Treglia G; Vogl U; Gillessen S; Pedrani M; Paone G, 2026, 'Imaging and Clinical Correlates of [177Lu]Lu-PSMA PET-Defined Eligibility in De Novo Metastatic Prostate Cancer', Biomedicines, 14, pp. 1818, http://dx.doi.org/10.3390/biomedicines14081818

Journal articles | 2026

Pecoraro G; De Giorgi A; Montelatici G; Salfi G; Lin H-M; Turco F; Taha T; Beltran H; de Bono J; Aggarwal RR; von Amsberg G; Joerger M; Imbimbo M; Colombo I; Gillessen S; Pedrani M, 2026, 'DLL3-Targeted Strategies in Advanced Prostate Cancer: Current Evidence and Future Perspectives', Drugs, 86, pp. 1489 - 1511, http://dx.doi.org/10.1007/s40265-026-02355-5

Journal articles | 2026

Pedrani M; Salfi G; Pecoraro G; Puglisi M; Turco F; Tortola L; Urechie V; Leone G; Lin HM; Vogl U; Barizzi J; Treglia G; Cuzzocrea M; Paone G; Lai P; Theurillat JP; Zilli T; Gillessen S; Merler S; Pereira Mestre R, 2026, 'Prognosis and Treatment Response in Aggressive-variant Prostate Cancer and Treatment-related Neuroendocrine Prostate Cancer: A Systematic Review and Meta-analysis', European Urology Oncology, 9, pp. 673 - 689, http://dx.doi.org/10.1016/j.euo.2026.01.011

Journal articles | 2026

Portman N; Mak B; Yeung N; Lin HM; Kim RMN; Mellor R; Ardolino L; Gutierrez D; Raneri M; Scheinberg T; Handelsman DJ; Moujaber T; Meikle PJ; Huynh K; Joshua AM; Hoy AJ; Butler L; Horvath LG, 2026, 'Characterising the effect of circulating sphingolipids on metastatic prostate cancer cells', Ebiomedicine, 123, http://dx.doi.org/10.1016/j.ebiom.2025.106058

Journal articles | 2026

Ricco V; Imbimbo M; Pedrani M; Gagliano A; Nerone M; Ciliberti EA; Badellino APA; Scahett N; Lin H-M; Tortola L; Coppola D; Bisdomini E; Mendonca ARC; Fossati A; Iannace M; Pallavicini L; Greco CC; Stathis A; Sessa C; Colombo I, 2026, '142P Early-phase clinical trials in gynaecologic malignancies: A 13-year single-center experience', ESMO Open, 11, pp. 108189, http://dx.doi.org/10.1016/j.esmoop.2026.108189

Journal articles | 2026

Saporita I; Calabrese M; Carfi FM; Mogavero A; Puglisi M; Treglia G; Vogl UM; Gillessen S; Pereira Mestre R; Pedrani M; Pecoraro G; Salfi G; Erhart C-C; Lin H-M; Tortola L; Di Maio M; Tucci M; Buttigliero C; Turco F, 2026, 'Risk of bone fractures in patients with prostate cancer treated with maximal androgen blockade therapy: a systematic literature review and meta-analysis', Prostate Cancer and Prostatic Diseases, 29, pp. 669 - 677, http://dx.doi.org/10.1038/s41391-026-01077-9

Journal articles | 2026

Talmor B; Marastoni S; Lau B; Yam A; Yeung N; Lin HM; Li ZJ; Woo H; Pranavan G; Stricker P; Horvath L; Koritzinsky M; Wouters B; Crumbaker M; Joshua A, 2026, 'A Phase I Study of Hydroxychloroquine and Suba-Itraconazole in Men with Biochemical Relapse of Prostate Cancer (HITMAN-PC): Dose Escalation Results', Cancer Research Communications, 6, pp. 687 - 697, http://dx.doi.org/10.1158/2767-9764.CRC-26-0010

Journal articles | 2026

Turco F; Gillessen S; Salfi G; Kloots ISH; Slootbeek PHJ; Mehra N; Labriola M; George DJ; Broderick A; Patrikidou A; Patry H; Buttigliero C; Crespi V; Uemura H; Fujita K; Utsumi T; Suzuki H; Raggi D; Basso U; Morales-Barrera R; Marmolejo Castaneda D; Sternberg CN; Guevara D; Caffo O; Procopio G; Zivi A; Merler S; Sorarù M; Spratt DE; C. Barata P; Messina C; ürün Y; Bolek H; Duràn I; Lavin JDC; Martínez Chanzá N; Horvath LG; Mellor R; Türkeri L; Soykök MB; Rossetti S; Cathomas R; Banna GL; Conteduca V; Ottaviano M; Marandino L; Lin HM; Tortola L; Pereira Mestre R; Pedrani M, 2026, 'EMETPRO: a multicentric, international, retrospective analysis evaluating patients with metastatic hormone-sensitive prostate cancer with early progression', Prostate Cancer and Prostatic Diseases, 29, pp. 862 - 874, http://dx.doi.org/10.1038/s41391-026-01124-5

Journal articles | 2025

Horvath L; Lin H-M; Davis ID; Martin AJ; Yeung N; Kim RM; Portman N; Joshua AM; McJannett MM; Subhash V; Yip S; North SA; McDermott RS; N. K; Stockler MR; Sweeney C; Group TAANZUAPCT, 2025, 'Association of circulating immune and metabolic markers with clinical outcomes in the ENZAMET trial (ANZUP 1304).', Journal of Clinical Oncology, 43, pp. 5093 - 5093, http://dx.doi.org/10.1200/jco.2025.43.16_suppl.5093

Journal articles | 2025

Lin HM; Scheinberg T; Portman N; Kim RMN; Mellor R; Huynh K; Faulkner AN; Mellett NA; Davis ID; Martin A; Sullivan D; Joshua A; McJannett M; Subhash V; Yip S; Azad AA; Marschner IC; North SA; McDermott RS; Chi KN; Stockler MR; Sweeney CJ; Meikle PJ; Horvath LG, 2025, 'Association of the circulating lipid panel, PCPro, with clinical outcomes in metastatic hormone-sensitive prostate cancer: post hoc analysis of the ENZAMET phase III randomised trial (ANZUP 1304)', Annals of Oncology, 36, pp. 1068 - 1077, http://dx.doi.org/10.1016/j.annonc.2025.05.529

Journal articles | 2025

Mellor R; Fitzpatrick M; Scheinberg T; Kim RM; Bonnitcha P; Sullivan D; Lin H-M; Davis ID; Martin AJ; Meikle P; Joshua AM; Mcjannett M; Subhash V; Yip S; North S; Mcdermott R; Chi KN; Stockler MR; Sweeney C; Horvath LG, 2025, 'PCPro, plasma lipid biomarker, in metastatic hormone-sensitive prostate cancer (mHSPC): from research to clinical implementation in the ENZAMET trial (ANZUP 1304)', ANNALS OF ONCOLOGY, 36, http://dx.doi.org/10.1016/j.annonc.2025.08.3098

Journal articles | 2025

Scheinberg T; Mellor R; Azad AA; Bonnitcha P; Buteau JP; Davis ID; Emmett L; Fitzpatrick M; Francis RJ; Kim RM; Kwan EM; Lin H-M; Martin AJ; Meikle P; Scott A; Stockler MR; Wyatt AW; Hofman MS; Horvath LG, 2025, '2392P PCPro as a prognostic plasma lipidomic biomarker in TheraP (ANZUP 1603): A randomised trial of [177Lu]Lu-PSMA-617 (LuPSMA) vs cabazitaxel in metastatic castration resistant prostate cancer (mCRPC)', Annals of Oncology, 36, pp. s1301 - s1302, http://dx.doi.org/10.1016/j.annonc.2025.08.3008

Journal articles | 2024

Horvath LG; Lin H-M; Davis ID; Martin A; Scheinberg T; Meikle P; Joshua A; Mcjannett M; Subhash V; Yip S; North S; McDermott RS; Chi KN; Stockler MR; Sweeney C, 2024, '1607P Association of the lipid biomarker, PCPro, and clinical outcomes in the ENZAMET trial (ANZUP 1304)', Annals of Oncology, 35, pp. S969 - S970, http://dx.doi.org/10.1016/j.annonc.2024.08.1688

Journal articles | 2024

Lin HM; Yang X; Centenera MM; Huynh K; Giles C; Dehairs J; Swinnen JV; Hoy AJ; Meikle PJ; Butler LM; Taplin ME; Horvath LG, 2024, 'Circulating Lipid Profiles Associated with Resistance to Androgen Deprivation Therapy in Localized Prostate Cancer', JCO Precision Oncology, 8, http://dx.doi.org/10.1200/PO.24.00260

Journal articles | 2024

Mahon KL; Sutherland SIM; Lin HM; Stockler MR; Gurney H; Mallesara G; Briscoe K; Marx G; Higano CS; de Bono JS; Chi KN; Clark G; Breit SN; Brown DA; Horvath LG, 2024, 'Clinical validation of circulating GDF15/MIC-1 as a marker of response to docetaxel and survival in men with metastatic castration-resistant prostate cancer', Prostate, 84, pp. 747 - 755, http://dx.doi.org/10.1002/pros.24691

Journal articles | 2024

Mellor R; Ardolino L; Scheinberg T; Fitzpatrick M; Lin HM; Bonnitcha P; Sullivan D; Meikle PJ; Stockler MR; Moujaber T; Joshua A; Horvath L, 2024, 'Evolocumab in metastatic castration-resistant prostate cancer: study protocol for a single-arm, phase II trial, and initial experience with use of a validated lipid biomarker to direct therapy', Therapeutic Advances in Medical Oncology, 16, http://dx.doi.org/10.1177/17588359241307814

Journal articles | 2024

Scheinberg T; Lin HM; Fitzpatrick M; Azad AA; Bonnitcha P; Davies A; Heller G; Huynh K; Mak B; Mahon K; Sullivan D; Meikle PJ; Horvath LG, 2024, 'PCPro: a clinically accessible, circulating lipid biomarker signature for poor-prognosis metastatic prostate cancer', Prostate Cancer and Prostatic Diseases, 27, pp. 136 - 143, http://dx.doi.org/10.1038/s41391-023-00666-2

Journal articles | 2024

Sharifi N; Diaz R; Lin HM; Roberts E; Horvath LG; Martin A; Stockler MR; Yip S; Subhash VV; Portman N; Davis ID; Sweeney CJ, 2024, 'Survival of men with metastatic hormone-sensitive prostate cancer and adrenal-permissive HSD3B1 inheritance', Journal of Clinical Investigation, 134, http://dx.doi.org/10.1172/JCI183583

Journal articles | 2024

Strach MC; Yeung N; Apostolov E; Wang T; Lin H-M; Ansari N; Koh C; Shin J-S; Kench J; Swarbrick A; Horvath L; Mahon KL, 2024, 'Abstract 5480: Single cell and spatial transcriptomic profile of appendiceal tumour peritoneal disease', Cancer Research, 84, pp. 5480 - 5480, http://dx.doi.org/10.1158/1538-7445.am2024-5480

Journal articles | 2024

Yeung N; Li T; Lin HM; Timmins HC; Goldstein D; Harrison M; Friedlander M; Mahon KL; Giles C; Meikle PJ; Park SB; Horvath LG, 2024, 'Plasma Lipidomic Profiling Identifies Elevated Triglycerides as Potential Risk Factor in Chemotherapy-Induced Peripheral Neuropathy', JCO Precision Oncology, 8, http://dx.doi.org/10.1200/PO.23.00690

Journal articles | 2023

Fang S; Zhe S; Lin HM; Azad AA; Fettke H; Kwan EM; Horvath L; Mak B; Zheng T; Du P; Jia S; Kirby RM; Kohli M, 2023, 'Multi-Omic Integration of Blood-Based Tumor-Associated Genomic and Lipidomic Profiles Using Machine Learning Models in Metastatic Prostate Cancer', JCO Clinical Cancer Informatics, 7, http://dx.doi.org/10.1200/CCI.23.00057

Journal articles | 2023

Horvath L; Lin H-M; Huynh K; Meikle T; Joshua AM; Azad A; Tan W; Butler L; Meikle P, 2023, 'Circulating ether lipids in prostate cancer.', JOURNAL OF CLINICAL ONCOLOGY, 41, pp. E17009 - E17009, http://dx.doi.org/10.1200/JCO.2023.41.16_suppl.e17009

Journal articles | 2023

Horvath LG; Kench C; Mellor R; Lin H-M; Mak B; Scheinberg T; Mahon K; Graham L; Azad AA; Joshua AM; Stockler MR; Marx GM; Briscoe K; Samaras K, 2023, '1831P Dissecting the meaning of obesity in metastatic castration resistant prostate cancer: Size or metabolism?', Annals of Oncology, 34, pp. s991, http://dx.doi.org/10.1016/j.annonc.2023.09.2779

Journal articles | 2023

Strach MC; Yeung N; Lin H-M; Ansari N; Koh C; Shin J-S; Kench J; Horvath L; Mahon KL, 2023, 'Characteristics of immune-infiltrating cells in the tumor microenvironment of appendiceal cancer with peritoneal disease.', Journal of Clinical Oncology, 41, pp. 217 - 217, http://dx.doi.org/10.1200/jco.2023.41.4_suppl.217

Journal articles | 2023

Yeung N; Lin H-M; Timmins H; Li T; Goldstein D; Friedlander M; Harrison ML; Mahon KL; Meikle P; Park S; Horvath L, 2023, 'Plasma lipidomic profiling of chemotherapy-induced peripheral neuropathy.', Journal of Clinical Oncology, 41, pp. 3031 - 3031, http://dx.doi.org/10.1200/jco.2023.41.16_suppl.3031

Journal articles | 2022

Centenera MM; Vincent AD; Moldovan M; Lin HM; Lynn DJ; Horvath LG; Butler LM, 2022, 'Harnessing the Heterogeneity of Prostate Cancer for Target Discovery Using Patient-Derived Explants', Cancers, 14, http://dx.doi.org/10.3390/cancers14071708

Journal articles | 2022

Mak B; Lin HM; Duong T; Mahon KL; Joshua AM; Stockler MR; Gurney H; Parnis F; Zhang A; Scheinberg T; Wittert G; Butler LM; Sullivan D; Hoy AJ; Meikle PJ; Horvath LG, 2022, 'Modulation of Plasma Lipidomic Profiles in Metastatic Castration-Resistant Prostate Cancer by Simvastatin', Cancers, 14, http://dx.doi.org/10.3390/cancers14194792

Journal articles | 2022

Mak B; Lin HM; Kwan EM; Fettke H; Tran B; Davis ID; Mahon K; Stockler MR; Briscoe K; Marx G; Zhang A; Crumbaker M; Tan W; Huynh K; Meikle TG; Mellett NA; Hoy AJ; Du P; Yu J; Jia S; Joshua AM; Waugh DJ; Butler LM; Kohli M; Meikle PJ; Azad AA; Horvath LG, 2022, 'Combined impact of lipidomic and genetic aberrations on clinical outcomes in metastatic castration-resistant prostate cancer', BMC Medicine, 20, http://dx.doi.org/10.1186/s12916-022-02298-0

Journal articles | 2022

Scheinberg T; Fitzpatrick M; Lin H-M; Azad AA; Bonnitcha P; Davies AG; Heller G; Huynh K; Mak B; Mahon K; Meikle P; Sullivan D; Horvath LG, 2022, '1409P Development of a clinically accessible, circulating prognostic lipid biomarker panel in men with mCRPC to guide potential metabolic intervention', Annals of Oncology, 33, pp. S1189 - S1189, http://dx.doi.org/10.1016/j.annonc.2022.07.1895

Journal articles | 2022

Strach MC; Yeung N; Apostolov E; Lin H-M; Nagaraju RT; Ansari N; Koh C; Shin J-S; Kench J; Aziz O; Swarbrick A; Horvath LG; Barriuso J; Mahon K, 2022, 'Single-cell transcriptomic analysis of appendiceal cancer peritoneal disease', ANNALS OF ONCOLOGY, vol. 33, pp. S1322 - S1322, http://dx.doi.org/10.1016/j.annonc.2022.07.1791

Journal articles | 2021

Lin HM; Huynh K; Kohli M; Tan W; Azad AA; Yeung N; Mahon KL; Mak B; Sutherland PD; Shepherd A; Mellett N; Docanto M; Giles C; Centenera MM; Butler LM; Meikle PJ; Horvath LG, 2021, 'Aberrations in circulating ceramide levels are associated with poor clinical outcomes across localised and metastatic prostate cancer', Prostate Cancer and Prostatic Diseases, 24, pp. 860 - 870, http://dx.doi.org/10.1038/s41391-021-00338-z

Journal articles | 2021

Lin HM; Mak B; Yeung N; Huynh K; Meikle TG; Mellett NA; Kwan EM; Fettke H; Tran B; Davis ID; Mahon KL; Zhang A; Stockler MR; Briscoe K; Marx G; Crumbaker M; Stricker PD; Du P; Yu J; Jia S; Scheinberg T; Fitzpatrick M; Bonnitcha P; Sullivan DR; Joshua AM; Azad AA; Butler LM; Meikle PJ; Horvath LG, 2021, 'Overcoming enzalutamide resistance in metastatic prostate cancer by targeting sphingosine kinase', Ebiomedicine, 72, http://dx.doi.org/10.1016/j.ebiom.2021.103625

Journal articles | 2021

Lin HM; Yeung N; Hastings JF; Croucher DR; Huynh K; Meikle TG; Mellett NA; Kwan EM; Davis ID; Tran B; Mahon KL; Zhang A; Stockler MR; Briscoe K; Marx G; Bastick P; Crumbaker ML; Joshua AM; Azad AA; Meikle PJ; Horvath LG, 2021, 'Relationship between circulating lipids and cytokines in metastatic castration‐resistant prostate cancer', Cancers, 13, http://dx.doi.org/10.3390/cancers13194964

Journal articles | 2019

Balaban S; Nassar ZD; Zhang AY; Hosseini-Beheshti E; Centenera MM; Schreuder M; Lin HM; Aishah A; Varney B; Liu-Fu F; Lee LS; Nagarajan SR; Shearer RF; Hardie RA; Raftopulos NL; Kakani MS; Saunders DN; Holst J; Horvath LG; Butler LM; Hoy AJ, 2019, 'Extracellular fatty acids are the major contributor to lipid synthesis in prostate cancer', Molecular Cancer Research, 17, pp. 949 - 962, http://dx.doi.org/10.1158/1541-7786.MCR-18-0347

Journal articles | 2019

Mahon K; Lin H; Lee-Ng M; Cain D; Jacobs C; Stockler M; Gurney H; Mallesara G; Briscoe K; Marx G; Higano C; de BJ; Chi K; Breit S; Brown D; Horvath L, 2019, 'Clinical validation of circulating cytokines as markers of prognosis and response to docetaxel in men with metastatic castration resistant prostate cancer', Oncology Abstracts, http://dx.doi.org/10.1530/oncolabs.1.p032

Journal articles | 2019

Mahon KL; Qu W; Lin HM; Spielman C; Cain D; Jacobs C; Stockler MR; Higano CS; de Bono JS; Chi KN; Clark SJ; Horvath LG, 2019, 'Serum Free Methylated Glutathione S-transferase 1 DNA Levels, Survival, and Response to Docetaxel in Metastatic, Castration-resistant Prostate Cancer: Post Hoc Analyses of Data from a Phase 3 Trial', European Urology, 76, pp. 306 - 312, http://dx.doi.org/10.1016/j.eururo.2018.11.001

Journal articles | 2018

Lin H-M; Nikolic I; Yang J; Castillo L; Deng N; Chan C-L; Yeung N; Dodson E; Elsworth B; Spielman C; Lee B; Boyer Z; Simpson K; Daly R; Horvath L; Swarbrick A, 2018, 'MicroRNAs as potential therapeutics to enhance chemosensitivity in advanced prostate cancer', , http://dx.doi.org/10.1101/273284

Journal articles | 2018

Lin HM; Lee BY; Castillo L; Spielman C; Grogan J; Yeung NK; Kench JG; Stricker PD; Haynes AM; Centenera MM; Butler LM; Shreeve SM; Horvath LG; Daly RJ, 2018, 'Effect of FAK inhibitor VS-6063 (defactinib) on docetaxel efficacy in prostate cancer', Prostate, 78, pp. 308 - 317, http://dx.doi.org/10.1002/pros.23476

Journal articles | 2018

Lin HM; Nikolic I; Yang J; Castillo L; Deng N; Chan CL; Yeung NK; Dodson E; Elsworth B; Spielman C; Lee BY; Boyer Z; Simpson KJ; Daly RJ; Horvath LG; Swarbrick A, 2018, 'MicroRNAs as potential therapeutics to enhance chemosensitivity in advanced prostate cancer', Scientific Reports, 8, http://dx.doi.org/10.1038/s41598-018-26050-y

Journal articles | 2017

Lin HM; Mahon KL; Spielman C; Gurney H; Mallesara G; Stockler MR; Bastick P; Briscoe K; Marx G; Swarbrick A; Horvath LG, 2017, 'Phase 2 study of circulating microRNA biomarkers in castration-resistant prostate cancer', British Journal of Cancer, 116, pp. 1002 - 1011, http://dx.doi.org/10.1038/bjc.2017.50

Journal articles | 2017

Lin HM; Mahon KL; Weir JM; Mundra PA; Spielman C; Briscoe K; Gurney H; Mallesara G; Marx G; Stockler MR; Prime C; Parton RG; Hoy AJ; Daly RJ; Meikle PJ; Horvath LG, 2017, 'A distinct plasma lipid signature associated with poor prognosis in castration-resistant prostate cancer', International Journal of Cancer, 141, pp. 2112 - 2120, http://dx.doi.org/10.1002/ijc.30903

Journal articles | 2017

Mahon KL; Qu W; Lin H-M; Spielman C; Cain D; Jacobs C; Chi KN; De Bono JS; Higano CS; Clark SJ; Horvath L, 2017, 'Post hoc analysis of a phase III study to test the association between circulating methylated glutathione s transferase (mGSTP1 ) DNA levels and response to docetaxel (DTX) in metastatic castration resistant prostate cancer (mCRPC).', Journal of Clinical Oncology, 35, pp. 5014 - 5014, http://dx.doi.org/10.1200/jco.2017.35.15_suppl.5014

Journal articles | 2016

Bruce HM; Stricker PD; Gupta R; Savdie RR; Haynes AM; Mahon KL; Lin HM; Kench JG; Horvath LG, 2016, 'Loss of AZGP1 as a Superior Predictor of Relapse in Margin-Positive Localized Prostate Cancer', Prostate, 76, pp. 1491 - 1500, http://dx.doi.org/10.1002/pros.23233

Journal articles | 2016

Mahon KL; Lin H-M; Spielman C; Lee-Ng M; Gurney H; Mallesara G; Stockler MR; Briscoe KP; Marx GM; Breit SN; Brown DA; Horvath L, 2016, 'Phase II trial of circulating cytokines as markers of docetaxel (DTX) resistance in metastatic castrate-resistant prostate cancer (mCRPC).', Journal of Clinical Oncology, 34, pp. 5039 - 5039, http://dx.doi.org/10.1200/jco.2016.34.15_suppl.5039

Journal articles | 2015

Mahon KL; Lin HM; Castillo L; Lee BY; Lee-Ng M; Chatfield MD; Chiam K; Breit SN; Brown DA; Molloy MP; Marx GM; Pavlakis N; Boyer MJ; Stockler MR; Daly RJ; Henshall SM; Horvath LG, 2015, 'Cytokine profiling of docetaxel-resistant castration-resistant prostate cancer', British Journal of Cancer, 112, pp. 1340 - 1348, http://dx.doi.org/10.1038/bjc.2015.74

Journal articles | 2014

Lin HM; Castillo L; Mahon KL; Chiam K; Lee BY; Nguyen Q; Boyer MJ; Stockler MR; Pavlakis N; Marx G; Mallesara G; Gurney H; Clark SJ; Swarbrick A; Daly RJ; Horvath LG, 2014, 'Circulating microRNAs are associated with docetaxel chemotherapy outcome in castration-resistant prostate cancer', British Journal of Cancer, 110, pp. 2462 - 2471, http://dx.doi.org/10.1038/bjc.2014.181

Journal articles | 2013

Horvath L; Chatfield MD; Lee-Ng M; Lin H-M; Castillo L; Breit SN; Brown DA; Molloy MP; Marx GM; Pavlakis N; Boyer MJ; Stockler MR; Wykes R; Henshall SM; Mahon KL, 2013, 'The role of macrophages in docetaxel (DTX) resistance in castrate-resistant prostate cancer (CRPC).', Journal of Clinical Oncology, 31, pp. e22175 - e22175, http://dx.doi.org/10.1200/jco.2013.31.15_suppl.e22175

Journal articles | 2013

Lee BY; Hochgraefe F; Lin H-M; Castillo L; Wu J; Raftery M; Shreeve SM; Horvath L; Daly R, 2013, 'Focal adhesion kinase: a mediator of docetaxel-resistance in castrate resistant prostate cancer', BJU INTERNATIONAL, 112, pp. 38 - 39, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000321969100100&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Journal articles | 2013

Lee BY; Hochgräfe F; Lin HM; Castillo L; Wu J; Raftery MJ; Martin Shreeve S; Horvath LG; Daly RJ, 2013, 'Phosphoproteomic profiling identifies focal adhesion kinase as a mediator of docetaxel resistance in castrate-resistant prostate cancer', Molecular Cancer Therapeutics, 13, pp. 190 - 201, http://dx.doi.org/10.1158/1535-7163.MCT-13-0225-T

Journal articles | 2011

Lin HM; Edmunds SJ; Zhu S; Helsby NA; Ferguson LR; Rowan DD, 2011, 'Metabolomic analysis reveals differences in urinary excretion of kiwifruit-derived metabolites in a mouse model of inflammatory bowel disease', Molecular Nutrition and Food Research, 55, pp. 1900 - 1904, http://dx.doi.org/10.1002/mnfr.201100302

Journal articles | 2011

Lin HM; Helsby NA; Rowan DD; Ferguson LR, 2011, 'Using metabolomic analysis to understand inflammatory bowel diseases', Inflammatory Bowel Diseases, 17, pp. 1021 - 1029, http://dx.doi.org/10.1002/ibd.21426

Journal articles | 2011

Otter D; Cao M; Lin HM; Fraser K; Edmunds S; Lane G; Rowan D, 2011, 'Identification of urinary biomarkers of colon inflammation in IL10 -/- mice using short-column LCMS metabolomics', Journal of Biomedicine and Biotechnology, 2011, http://dx.doi.org/10.1155/2011/974701

Journal articles | 2010

Lin HM; Barnett MPG; Roy NC; Joyce NI; Zhu S; Armstrong K; Helsby NA; Ferguson LR; Rowan DD, 2010, 'Metabolomic analysis identifies inflammatory and noninflammatory metabolic effects of genetic modification in a mouse model of Crohn?s disease', Journal of Proteome Research, 9, pp. 1965 - 1975, http://dx.doi.org/10.1021/pr901130s

Journal articles | 2009

Lin HM; Edmunds SJ; Helsby NA; Ferguson LR; Rowan DD, 2009, 'Nontargeted urinary metabolite profiling of a mouse model of crohn's disease', Journal of Proteome Research, 8, pp. 2045 - 2057, http://dx.doi.org/10.1021/pr800999t

Journal articles | 2007

Lin HM; Chatterjee A; Lin YH; Anjomshoaa A; Fukuzawa R; McCall JL; Reeve AE, 2007, 'Genome wide expression profiling identifies genes associated with colorectal liver metastasis', Oncology Reports, 17, pp. 1541 - 1549, http://dx.doi.org/10.3892/or.17.6.1541

Journal articles | 2005

Lin HM; Gerrard JA; Shaw IC, 2005, 'Stability of the insecticide cypermethrin during tomato processing and implications for endocrine activity', Food Additives and Contaminants, 22, pp. 15 - 22, http://dx.doi.org/10.1080/02652030400027938

Journal articles | 2005

Rasiah IA; Sutton KH; Low FL; Lin HM; Gerrard JA, 2005, 'Crosslinking of wheat dough proteins by glucose oxidase and the resulting effects on bread and croissants', Food Chemistry, 89, pp. 325 - 332, http://dx.doi.org/10.1016/j.foodchem.2004.02.052

Journal articles | 2004

Low F; Lin HM; Gerrard JA; Cressey PJ; Shaw IC, 2004, 'Ranking the risk of pesticide dietary intake', Pest Management Science, 60, pp. 842 - 848, http://dx.doi.org/10.1002/ps.904
Other | 2026

Medina S; Tokuyama N; Putcha V; Pathak T; Fu P; Thomas H; Subhash VV; Yip S; Lin H-M; Horvath LG; Kench JG; Zhang A; Stockler MR; Joshua AM; Azad A; Oakes SR; Davis ID; Sweeney CJ; Madabhushi A, 2026, Data from AI-Based Pathology Classifier Predicts Sensitivity to Enzalutamide in Metastatic Hormone-Sensitive Prostate Cancer: A Biomarker Analysis of the ENZAMET Trial, http://dx.doi.org/10.1158/1078-0432.c.8775251

Other | 2026

Medina S; Tokuyama N; Putcha V; Pathak T; Fu P; Thomas H; Subhash VV; Yip S; Lin H-M; Horvath LG; Kench JG; Zhang A; Stockler MR; Joshua AM; Azad A; Oakes SR; Davis ID; Sweeney CJ; Madabhushi A, 2026, Supplementary Figure S1 from AI-Based Pathology Classifier Predicts Sensitivity to Enzalutamide in Metastatic Hormone-Sensitive Prostate Cancer: A Biomarker Analysis of the ENZAMET Trial, http://dx.doi.org/10.1158/1078-0432.34520069

Other | 2026

Medina S; Tokuyama N; Putcha V; Pathak T; Fu P; Thomas H; Subhash VV; Yip S; Lin H-M; Horvath LG; Kench JG; Zhang A; Stockler MR; Joshua AM; Azad A; Oakes SR; Davis ID; Sweeney CJ; Madabhushi A, 2026, Supplementary Figure S10 from AI-Based Pathology Classifier Predicts Sensitivity to Enzalutamide in Metastatic Hormone-Sensitive Prostate Cancer: A Biomarker Analysis of the ENZAMET Trial, http://dx.doi.org/10.1158/1078-0432.34520066

Other | 2026

Medina S; Tokuyama N; Putcha V; Pathak T; Fu P; Thomas H; Subhash VV; Yip S; Lin H-M; Horvath LG; Kench JG; Zhang A; Stockler MR; Joshua AM; Azad A; Oakes SR; Davis ID; Sweeney CJ; Madabhushi A, 2026, Supplementary Figure S2 from AI-Based Pathology Classifier Predicts Sensitivity to Enzalutamide in Metastatic Hormone-Sensitive Prostate Cancer: A Biomarker Analysis of the ENZAMET Trial, http://dx.doi.org/10.1158/1078-0432.34520063

Other | 2026

Medina S; Tokuyama N; Putcha V; Pathak T; Fu P; Thomas H; Subhash VV; Yip S; Lin H-M; Horvath LG; Kench JG; Zhang A; Stockler MR; Joshua AM; Azad A; Oakes SR; Davis ID; Sweeney CJ; Madabhushi A, 2026, Supplementary Figure S3 from AI-Based Pathology Classifier Predicts Sensitivity to Enzalutamide in Metastatic Hormone-Sensitive Prostate Cancer: A Biomarker Analysis of the ENZAMET Trial, http://dx.doi.org/10.1158/1078-0432.34520060

Other | 2026

Medina S; Tokuyama N; Putcha V; Pathak T; Fu P; Thomas H; Subhash VV; Yip S; Lin H-M; Horvath LG; Kench JG; Zhang A; Stockler MR; Joshua AM; Azad A; Oakes SR; Davis ID; Sweeney CJ; Madabhushi A, 2026, Supplementary Figure S4 from AI-Based Pathology Classifier Predicts Sensitivity to Enzalutamide in Metastatic Hormone-Sensitive Prostate Cancer: A Biomarker Analysis of the ENZAMET Trial, http://dx.doi.org/10.1158/1078-0432.34520057

Other | 2026

Medina S; Tokuyama N; Putcha V; Pathak T; Fu P; Thomas H; Subhash VV; Yip S; Lin H-M; Horvath LG; Kench JG; Zhang A; Stockler MR; Joshua AM; Azad A; Oakes SR; Davis ID; Sweeney CJ; Madabhushi A, 2026, Supplementary Figure S5 from AI-Based Pathology Classifier Predicts Sensitivity to Enzalutamide in Metastatic Hormone-Sensitive Prostate Cancer: A Biomarker Analysis of the ENZAMET Trial, http://dx.doi.org/10.1158/1078-0432.34520054

Other | 2026

Medina S; Tokuyama N; Putcha V; Pathak T; Fu P; Thomas H; Subhash VV; Yip S; Lin H-M; Horvath LG; Kench JG; Zhang A; Stockler MR; Joshua AM; Azad A; Oakes SR; Davis ID; Sweeney CJ; Madabhushi A, 2026, Supplementary Figure S6 from AI-Based Pathology Classifier Predicts Sensitivity to Enzalutamide in Metastatic Hormone-Sensitive Prostate Cancer: A Biomarker Analysis of the ENZAMET Trial, http://dx.doi.org/10.1158/1078-0432.34520051

Other | 2026

Medina S; Tokuyama N; Putcha V; Pathak T; Fu P; Thomas H; Subhash VV; Yip S; Lin H-M; Horvath LG; Kench JG; Zhang A; Stockler MR; Joshua AM; Azad A; Oakes SR; Davis ID; Sweeney CJ; Madabhushi A, 2026, Supplementary Figure S7 from AI-Based Pathology Classifier Predicts Sensitivity to Enzalutamide in Metastatic Hormone-Sensitive Prostate Cancer: A Biomarker Analysis of the ENZAMET Trial, http://dx.doi.org/10.1158/1078-0432.34520045

Other | 2026

Medina S; Tokuyama N; Putcha V; Pathak T; Fu P; Thomas H; Subhash VV; Yip S; Lin H-M; Horvath LG; Kench JG; Zhang A; Stockler MR; Joshua AM; Azad A; Oakes SR; Davis ID; Sweeney CJ; Madabhushi A, 2026, Supplementary Figure S8 from AI-Based Pathology Classifier Predicts Sensitivity to Enzalutamide in Metastatic Hormone-Sensitive Prostate Cancer: A Biomarker Analysis of the ENZAMET Trial, http://dx.doi.org/10.1158/1078-0432.34520039

Other | 2026

Medina S; Tokuyama N; Putcha V; Pathak T; Fu P; Thomas H; Subhash VV; Yip S; Lin H-M; Horvath LG; Kench JG; Zhang A; Stockler MR; Joshua AM; Azad A; Oakes SR; Davis ID; Sweeney CJ; Madabhushi A, 2026, Supplementary Figure S9 from AI-Based Pathology Classifier Predicts Sensitivity to Enzalutamide in Metastatic Hormone-Sensitive Prostate Cancer: A Biomarker Analysis of the ENZAMET Trial, http://dx.doi.org/10.1158/1078-0432.34520033

Other | 2026

Medina S; Tokuyama N; Putcha V; Pathak T; Fu P; Thomas H; Subhash VV; Yip S; Lin H-M; Horvath LG; Kench JG; Zhang A; Stockler MR; Joshua AM; Azad A; Oakes SR; Davis ID; Sweeney CJ; Madabhushi A, 2026, Supplementary Methods 1 from AI-Based Pathology Classifier Predicts Sensitivity to Enzalutamide in Metastatic Hormone-Sensitive Prostate Cancer: A Biomarker Analysis of the ENZAMET Trial, http://dx.doi.org/10.1158/1078-0432.34520030

Other | 2026

Medina S; Tokuyama N; Putcha V; Pathak T; Fu P; Thomas H; Subhash VV; Yip S; Lin H-M; Horvath LG; Kench JG; Zhang A; Stockler MR; Joshua AM; Azad A; Oakes SR; Davis ID; Sweeney CJ; Madabhushi A, 2026, Supplementary Results 1 from AI-Based Pathology Classifier Predicts Sensitivity to Enzalutamide in Metastatic Hormone-Sensitive Prostate Cancer: A Biomarker Analysis of the ENZAMET Trial, http://dx.doi.org/10.1158/1078-0432.34520024

Other | 2026

Medina S; Tokuyama N; Putcha V; Pathak T; Fu P; Thomas H; Subhash VV; Yip S; Lin H-M; Horvath LG; Kench JG; Zhang A; Stockler MR; Joshua AM; Azad A; Oakes SR; Davis ID; Sweeney CJ; Madabhushi A, 2026, Supplementary Table S1 from AI-Based Pathology Classifier Predicts Sensitivity to Enzalutamide in Metastatic Hormone-Sensitive Prostate Cancer: A Biomarker Analysis of the ENZAMET Trial, http://dx.doi.org/10.1158/1078-0432.34520021

Other | 2026

Medina S; Tokuyama N; Putcha V; Pathak T; Fu P; Thomas H; Subhash VV; Yip S; Lin H-M; Horvath LG; Kench JG; Zhang A; Stockler MR; Joshua AM; Azad A; Oakes SR; Davis ID; Sweeney CJ; Madabhushi A, 2026, Supplementary Table S2 from AI-Based Pathology Classifier Predicts Sensitivity to Enzalutamide in Metastatic Hormone-Sensitive Prostate Cancer: A Biomarker Analysis of the ENZAMET Trial, http://dx.doi.org/10.1158/1078-0432.34520018

Other | 2026

Medina S; Tokuyama N; Putcha V; Pathak T; Fu P; Thomas H; Subhash VV; Yip S; Lin H-M; Horvath LG; Kench JG; Zhang A; Stockler MR; Joshua AM; Azad A; Oakes SR; Davis ID; Sweeney CJ; Madabhushi A, 2026, Supplementary Table S3 from AI-Based Pathology Classifier Predicts Sensitivity to Enzalutamide in Metastatic Hormone-Sensitive Prostate Cancer: A Biomarker Analysis of the ENZAMET Trial, http://dx.doi.org/10.1158/1078-0432.34520015

Other | 2026

Medina S; Tokuyama N; Putcha V; Pathak T; Fu P; Thomas H; Subhash VV; Yip S; Lin H-M; Horvath LG; Kench JG; Zhang A; Stockler MR; Joshua AM; Azad A; Oakes SR; Davis ID; Sweeney CJ; Madabhushi A, 2026, Supplementary Table S4 from AI-Based Pathology Classifier Predicts Sensitivity to Enzalutamide in Metastatic Hormone-Sensitive Prostate Cancer: A Biomarker Analysis of the ENZAMET Trial, http://dx.doi.org/10.1158/1078-0432.34520012

Conference Abstracts | 2026

Medina SR; Tokuyama N; Putcha V; Pathak T; Fu P; Thomas H; Subhash V; Yip S; Lin H-M; Horvath L; Kench JG; Zhang AY; Stockler MR; Joshua AM; Azad A; Oakes SR; Davis ID; Sweeney C; Madabhushi A, 2026, 'An AI-based pathology classifier to predict benefit from enzalutamide in metastatic hormone-sensitive prostate cancer (mHSPC) from ENZAMET (ANZUP 1304).', in Journal of Clinical Oncology, American Society of Clinical Oncology (ASCO), Vol. 44, pp. 108 - 108, http://dx.doi.org/10.1200/jco.2026.44.16_suppl.108

Other | 2026

Talmor B; Marastoni S; Lau B; Yam AO; Yeung N; Lin H-M; Li ZJ; Woo H; Pranavan G; Stricker PD; Horvath LG; Koritzinsky M; Wouters BG; Crumbaker M; Joshua AM, 2026, Data from A Phase I Study of Hydroxychloroquine and Suba-Itraconazole in Men with Biochemical Relapse of Prostate Cancer (HITMAN-PC): Dose Escalation Results, http://dx.doi.org/10.1158/2767-9764.c.8387594

Other | 2026

Talmor B; Marastoni S; Lau B; Yam AO; Yeung N; Lin H-M; Li ZJ; Woo H; Pranavan G; Stricker PD; Horvath LG; Koritzinsky M; Wouters BG; Crumbaker M; Joshua AM, 2026, Figure 1 from A Phase I Study of Hydroxychloroquine and Suba-Itraconazole in Men with Biochemical Relapse of Prostate Cancer (HITMAN-PC): Dose Escalation Results, http://dx.doi.org/10.1158/2767-9764.31872536

Other | 2026

Talmor B; Marastoni S; Lau B; Yam AO; Yeung N; Lin H-M; Li ZJ; Woo H; Pranavan G; Stricker PD; Horvath LG; Koritzinsky M; Wouters BG; Crumbaker M; Joshua AM, 2026, Figure 2 from A Phase I Study of Hydroxychloroquine and Suba-Itraconazole in Men with Biochemical Relapse of Prostate Cancer (HITMAN-PC): Dose Escalation Results, http://dx.doi.org/10.1158/2767-9764.31872533

Other | 2026

Talmor B; Marastoni S; Lau B; Yam AO; Yeung N; Lin H-M; Li ZJ; Woo H; Pranavan G; Stricker PD; Horvath LG; Koritzinsky M; Wouters BG; Crumbaker M; Joshua AM, 2026, Figure 3 from A Phase I Study of Hydroxychloroquine and Suba-Itraconazole in Men with Biochemical Relapse of Prostate Cancer (HITMAN-PC): Dose Escalation Results, http://dx.doi.org/10.1158/2767-9764.31872530

Other | 2026

Talmor B; Marastoni S; Lau B; Yam AO; Yeung N; Lin H-M; Li ZJ; Woo H; Pranavan G; Stricker PD; Horvath LG; Koritzinsky M; Wouters BG; Crumbaker M; Joshua AM, 2026, Figure 4 from A Phase I Study of Hydroxychloroquine and Suba-Itraconazole in Men with Biochemical Relapse of Prostate Cancer (HITMAN-PC): Dose Escalation Results, http://dx.doi.org/10.1158/2767-9764.31872527

Other | 2026

Talmor B; Marastoni S; Lau B; Yam AO; Yeung N; Lin H-M; Li ZJ; Woo H; Pranavan G; Stricker PD; Horvath LG; Koritzinsky M; Wouters BG; Crumbaker M; Joshua AM, 2026, Supplementary Figure 1 from A Phase I Study of Hydroxychloroquine and Suba-Itraconazole in Men with Biochemical Relapse of Prostate Cancer (HITMAN-PC): Dose Escalation Results, http://dx.doi.org/10.1158/2767-9764.31872524

Other | 2026

Talmor B; Marastoni S; Lau B; Yam AO; Yeung N; Lin H-M; Li ZJ; Woo H; Pranavan G; Stricker PD; Horvath LG; Koritzinsky M; Wouters BG; Crumbaker M; Joshua AM, 2026, Supplementary Figure 2 from A Phase I Study of Hydroxychloroquine and Suba-Itraconazole in Men with Biochemical Relapse of Prostate Cancer (HITMAN-PC): Dose Escalation Results, http://dx.doi.org/10.1158/2767-9764.31872521

Other | 2026

Talmor B; Marastoni S; Lau B; Yam AO; Yeung N; Lin H-M; Li ZJ; Woo H; Pranavan G; Stricker PD; Horvath LG; Koritzinsky M; Wouters BG; Crumbaker M; Joshua AM, 2026, Supplementary Figure 3 from A Phase I Study of Hydroxychloroquine and Suba-Itraconazole in Men with Biochemical Relapse of Prostate Cancer (HITMAN-PC): Dose Escalation Results, http://dx.doi.org/10.1158/2767-9764.31872518

Other | 2026

Talmor B; Marastoni S; Lau B; Yam AO; Yeung N; Lin H-M; Li ZJ; Woo H; Pranavan G; Stricker PD; Horvath LG; Koritzinsky M; Wouters BG; Crumbaker M; Joshua AM, 2026, Supplementary Figure 4 from A Phase I Study of Hydroxychloroquine and Suba-Itraconazole in Men with Biochemical Relapse of Prostate Cancer (HITMAN-PC): Dose Escalation Results, http://dx.doi.org/10.1158/2767-9764.31872515

Other | 2026

Talmor B; Marastoni S; Lau B; Yam AO; Yeung N; Lin H-M; Li ZJ; Woo H; Pranavan G; Stricker PD; Horvath LG; Koritzinsky M; Wouters BG; Crumbaker M; Joshua AM, 2026, Supplementary Figure 5 from A Phase I Study of Hydroxychloroquine and Suba-Itraconazole in Men with Biochemical Relapse of Prostate Cancer (HITMAN-PC): Dose Escalation Results, http://dx.doi.org/10.1158/2767-9764.31872512

Other | 2026

Talmor B; Marastoni S; Lau B; Yam AO; Yeung N; Lin H-M; Li ZJ; Woo H; Pranavan G; Stricker PD; Horvath LG; Koritzinsky M; Wouters BG; Crumbaker M; Joshua AM, 2026, Supplementary Figure 6 from A Phase I Study of Hydroxychloroquine and Suba-Itraconazole in Men with Biochemical Relapse of Prostate Cancer (HITMAN-PC): Dose Escalation Results, http://dx.doi.org/10.1158/2767-9764.31872509

Other | 2026

Talmor B; Marastoni S; Lau B; Yam AO; Yeung N; Lin H-M; Li ZJ; Woo H; Pranavan G; Stricker PD; Horvath LG; Koritzinsky M; Wouters BG; Crumbaker M; Joshua AM, 2026, Supplementary Table 1 from A Phase I Study of Hydroxychloroquine and Suba-Itraconazole in Men with Biochemical Relapse of Prostate Cancer (HITMAN-PC): Dose Escalation Results, http://dx.doi.org/10.1158/2767-9764.31872506

Other | 2026

Talmor B; Marastoni S; Lau B; Yam AO; Yeung N; Lin H-M; Li ZJ; Woo H; Pranavan G; Stricker PD; Horvath LG; Koritzinsky M; Wouters BG; Crumbaker M; Joshua AM, 2026, Supplementary Table 2 from A Phase I Study of Hydroxychloroquine and Suba-Itraconazole in Men with Biochemical Relapse of Prostate Cancer (HITMAN-PC): Dose Escalation Results, http://dx.doi.org/10.1158/2767-9764.31872503

Other | 2026

Talmor B; Marastoni S; Lau B; Yam AO; Yeung N; Lin H-M; Li ZJ; Woo H; Pranavan G; Stricker PD; Horvath LG; Koritzinsky M; Wouters BG; Crumbaker M; Joshua AM, 2026, Table 1 from A Phase I Study of Hydroxychloroquine and Suba-Itraconazole in Men with Biochemical Relapse of Prostate Cancer (HITMAN-PC): Dose Escalation Results, http://dx.doi.org/10.1158/2767-9764.31872500

Other | 2026

Talmor B; Marastoni S; Lau B; Yam AO; Yeung N; Lin H-M; Li ZJ; Woo H; Pranavan G; Stricker PD; Horvath LG; Koritzinsky M; Wouters BG; Crumbaker M; Joshua AM, 2026, Table 2 from A Phase I Study of Hydroxychloroquine and Suba-Itraconazole in Men with Biochemical Relapse of Prostate Cancer (HITMAN-PC): Dose Escalation Results, http://dx.doi.org/10.1158/2767-9764.31872497

Conference Abstracts | 2025

Mellor R; Fitzpatrick M; Scheinberg T; Kim RM; Bonnitcha P; Sullivan D; Lin H-M; Davis ID; Martin AJ; Meikle P; Joshua AM; Mcjannett M; Subhash V; Yip S; North S; McDermott R; Chi KN; Stockler MR; Sweeney C; Horvath LG, 2025, '2483P PCPro, plasma lipid biomarker, in metastatic hormone-sensitive prostate cancer (mHSPC): from research to clinical implementation in the ENZAMET trial (ANZUP 1304)', in Annals of Oncology, Elsevier, Vol. 36, pp. s1347 - s1348, http://dx.doi.org/10.1016/j.annonc.2025.08.3098

Conference Abstracts | 2024

Horvath LG; Lin H-M; Davis ID; Martin A; Scheinberg T; Meikle P; Joshua A; Mcjannett M; Subhash V; Yip S; North S; McDermott RS; Chi KN; Stockler MR; Sweeney C, 2024, 'Association of the lipid biomarker, PCPro, and clinical outcomes in the ENZAMET trial (ANZUP 1304)', in ANNALS OF ONCOLOGY, ELSEVIER, SPAIN, Barcelona, Vol. 35, pp. S969 - S970, presented at Annual Congress of the European-Society-for-Medical-Oncology (ESMO), SPAIN, Barcelona, 13 September 2024 - 17 September 2024, http://dx.doi.org/10.1016/j.annonc.2024.08.1688

Conference Abstracts | 2024

Strach MC; Yeung N; Apostolov E; Wang T; Lin H-M; Ansari N; Koh C; Shin J-S; Kench J; Swarbrick A; Horvath L; Mahon KL, 2024, 'Abstract 5480: Single cell and spatial transcriptomic profile of appendiceal tumour peritoneal disease', in Cancer Research, American Association for Cancer Research (AACR), Vol. 84, pp. 5480 - 5480, http://dx.doi.org/10.1158/1538-7445.am2024-5480

Other | 2023

Balaban S; Nassar ZD; Zhang AY; Hosseini-Beheshti E; Centenera MM; Schreuder M; Lin H-M; Aishah A; Varney B; Liu-Fu F; Lee LS; Nagarajan SR; Shearer RF; Hardie R-A; Raftopulos NL; Kakani MS; Saunders DN; Holst J; Horvath LG; Butler LM; Hoy AJ, 2023, Data from Extracellular Fatty Acids Are the Major Contributor to Lipid Synthesis in Prostate Cancer, http://dx.doi.org/10.1158/1541-7786.c.6540204

Other | 2023

Balaban S; Nassar ZD; Zhang AY; Hosseini-Beheshti E; Centenera MM; Schreuder M; Lin H-M; Aishah A; Varney B; Liu-Fu F; Lee LS; Nagarajan SR; Shearer RF; Hardie R-A; Raftopulos NL; Kakani MS; Saunders DN; Holst J; Horvath LG; Butler LM; Hoy AJ, 2023, Data from Extracellular Fatty Acids Are the Major Contributor to Lipid Synthesis in Prostate Cancer, http://dx.doi.org/10.1158/1541-7786.c.6540204.v1

Other | 2023

Balaban S; Nassar ZD; Zhang AY; Hosseini-Beheshti E; Centenera MM; Schreuder M; Lin H-M; Aishah A; Varney B; Liu-Fu F; Lee LS; Nagarajan SR; Shearer RF; Hardie R-A; Raftopulos NL; Kakani MS; Saunders DN; Holst J; Horvath LG; Butler LM; Hoy AJ, 2023, Supplementary Figures 1-3 from Extracellular Fatty Acids Are the Major Contributor to Lipid Synthesis in Prostate Cancer, http://dx.doi.org/10.1158/1541-7786.22512309

Other | 2023

Balaban S; Nassar ZD; Zhang AY; Hosseini-Beheshti E; Centenera MM; Schreuder M; Lin H-M; Aishah A; Varney B; Liu-Fu F; Lee LS; Nagarajan SR; Shearer RF; Hardie R-A; Raftopulos NL; Kakani MS; Saunders DN; Holst J; Horvath LG; Butler LM; Hoy AJ, 2023, Supplementary Figures 1-3 from Extracellular Fatty Acids Are the Major Contributor to Lipid Synthesis in Prostate Cancer, http://dx.doi.org/10.1158/1541-7786.22512309.v1

Conference Papers | 2023

Horvath L; Lin H-M; Huynh K; Meikle T; Joshua AM; Azad A; Tan W; Meikle P, 2023, 'Circulating ether lipids in prostate cancer', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, IL, Chicago, presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), IL, Chicago, 02 June 2023 - 06 June 2023

Conference Papers | 2023

Mellor R; Ardolino L; Scheinberg T; Sullivan D; Lin H-M; Meikle P; Stockler M; Joshua A; Horvath L, 2023, 'Evolocumab in Metastatic Castration-Resistant Prostate Cancer - study schema', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY, pp. 68 - 68

Conference Papers | 2023

Scheinberg T; Lin H-M; Fitzpatrick M; Azad A; Bonnitcha P; Davies A; Heller G; Huynh K; Mak B; Mahon K; Mellor R; Sullivan D; Meikle P; Horvath L, 2023, 'PCPro: a clinically accessible, circulating lipid biomarker signature for poor-prognosis metastatic prostate cancer', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY, pp. 84 - 84

Conference Papers | 2023

Yeung N; Lin H-M; Timmins H; Li T; Goldstein D; Friedlander M; Harrison ML; Mahon KL; Meikle P; Park S; Horvath L, 2023, 'Plasma lipidomic profiling of chemotherapy-induced peripheral neuropathy', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, IL, Chicago, presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), IL, Chicago, 02 June 2023 - 06 June 2023

Conference Abstracts | 2022

Mak B; Lin H-M; Mahon KL; Joshua AM; Stockler MR; Gurney H; Parnis F; Zhang AY; Scheinberg T; Wittert G; Butler L; Hoy A; Meikle P; Horvath L, 2022, 'Modulation of the plasma lipidomic profile with simvastatin in metastatic castration-resistant prostate cancer (mCRPC).', in Journal of Clinical Oncology, American Society of Clinical Oncology (ASCO), Vol. 40, pp. 154 - 154, http://dx.doi.org/10.1200/jco.2022.40.6_suppl.154

Conference Abstracts | 2022

Strach MC; Yeung N; Apostolov E; Lin H-M; Nagaraju RT; Ansari N; Koh C; Shin J-S; Kench J; Aziz O; Swarbrick A; Horvath LG; Barriuso J; Mahon K, 2022, '1713P Single-cell transcriptomic analysis of appendiceal cancer peritoneal disease', in Annals of Oncology, Elsevier, Vol. 33, pp. s1322, http://dx.doi.org/10.1016/j.annonc.2022.07.1791

Conference Abstracts | 2022

Strach MC; Yeung N; Lin H-M; Ansari N; Koh C; Shin J-S; Kench J; Centenera M; Butler L; Horvath L; Mahon K, 2022, 'Patient-derived explant model of appendiceal cancer.', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, ELECTR NETWORK, Vol. 40, presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), ELECTR NETWORK, 03 June 2022 - 07 June 2022

Conference Abstracts | 2022

Strach MC; Yeung N; Lin H-M; Ansari N; Koh C; Shin J-S; Kench J; Centenera M; Butler L; Horvath L; Mahon K, 2022, 'Patient-derived explant model of appendiceal cancer.', in Journal of Clinical Oncology, American Society of Clinical Oncology (ASCO), Vol. 40, pp. 4160 - 4160, http://dx.doi.org/10.1200/jco.2022.40.16_suppl.4160

Conference Abstracts | 2021

Lin H-M; Mak B; Huynh K; Kwan EM; Fettke H; Tran B; Davis ID; Mahon KL; Stockler MR; Briscoe K; Marx GM; Du P; Yu J; Jia S; Joshua AM; Azad AA; Butler LM; Meikle PJ; Horvath LG, 2021, '635P Association of ceramide metabolism with resistance to androgen receptor signalling inhibitors in metastatic prostate cancer', in Annals of Oncology, Elsevier, Vol. 32, pp. s666 - s667, http://dx.doi.org/10.1016/j.annonc.2021.08.1148

Conference Abstracts | 2021

Mak B; Lin H-M; Kwan EM; Fettke H; Tran B; Davis ID; Mahon KL; Stockler MR; Briscoe K; Marx GM; Kohli M; Tan W; Huynh K; Du P; Yu J; Jia S; Joshua AM; Azad AA; Meikle PJ; Horvath LG, 2021, '596P Impact of combined lipidomic and genetic aberrations on clinical outcomes in metastatic castration-resistant prostate cancer (mCRPC)', in Annals of Oncology, Elsevier, Vol. 32, pp. s642 - s643, http://dx.doi.org/10.1016/j.annonc.2021.08.1109

Conference Abstracts | 2020

Horvath LG; Lin H-M; Mak B; Mahon K; Yeung N; Docanto M; Sutherland P; Shepherd A; Tan W; Azad A; Kohli M; Meikle P; Butler L, 2020, 'Abstract 4761: Lipidomic analysis of circulating lipids across the natural history of prostate cancer identifies aberrant ceramide metabolism', in Cancer Research, American Association for Cancer Research (AACR), Vol. 80, pp. 4761 - 4761, http://dx.doi.org/10.1158/1538-7445.am2020-4761

Conference Abstracts | 2019

, 2019, 'Company Profiles', in Asia-Pacific Journal of Clinical Oncology, Wiley, Vol. 15, pp. 69 - 71, http://dx.doi.org/10.1111/ajco.13198

Conference Abstracts | 2019

Mahon KL; Lin H-M; Lee-Ng M; Stockler MR; Gurney H; Mallesara G; Briscoe KP; Marx GM; Higano CS; De Bono JS; N. K; Brown D; Breit SN; Horvath L, 2019, 'Clinical validation of circulating cytokines as markers of prognosis and response to docetaxel in men with metastatic castration-resistant prostate cancer.', in Journal of Clinical Oncology, American Society of Clinical Oncology (ASCO), Vol. 37, pp. 230 - 230, http://dx.doi.org/10.1200/jco.2019.37.7_suppl.230

Conference Papers | 2017

Horvath L; Lin H-M; Mahon KL; Weir J; Mundra P; Spielman C; Briscoe KP; Gurney H; Mallesara G; Marx GM; Stockler MR; Parton R; Hoy A; Daly RJ; Meikle P, 2017, 'The plasma lipidome in castration-resistant prostate cancer.', in Journal of Clinical Oncology, American Society of Clinical Oncology (ASCO), pp. 5055 - 5055, http://dx.doi.org/10.1200/jco.2017.35.15_suppl.5055

Conference Papers | 2013

Horvath L; Chatfield MD; Lee-Ng M; Lin H-M; Castillo L; Breit SN; Brown DA; Molloy MP; Marx GM; Pavlakis N; Boyer MJ; Stockier MR; Wykes R; Henshall SM; Mahon KL, 2013, 'The role of macrophages in docetaxel (DTX) resistance in castrate-resistant prostate cancer (CRPC).', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, IL, Chicago, presented at 49th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), IL, Chicago, 31 May 2013 - 04 June 2013, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000335419605294&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Conference Papers | 2012

Lee BY; Hochgraefe F; Lin HM; Castillo L; Raftery M; Horvath LG; Daly RJ, 2012, 'Overcoming Docetaxel Resistance in Prostate Cancer by Targeting FAK Phosphorylation, and Its Mode of Action', in EUROPEAN JOURNAL OF CANCER, ELSEVIER SCI LTD, IRELAND, European Org Res & Treatment Canc (EORTC), Dublin, pp. 48 - 49, presented at 24th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, IRELAND, European Org Res & Treatment Canc (EORTC), Dublin, 06 November 2012 - 09 November 2012, http://dx.doi.org/10.1016/S0959-8049(12)71956-1

Preprints |

Lin H-M; Nikolic I; Yang J; Castillo L; Deng N; Chan C-L; Yeung NK; Dodson E; Elsworth B; Spielman C; Lee BY; Boyer Z; Simpson KJ; Daly RJ; Horvath LG; Swarbrick A, MicroRNAs as potential therapeutics to enhance chemosensitivity in advanced prostate cancer, http://dx.doi.org/10.1101/273284

Follow

Dr Hui-Ming Lin